Charles River Laboratories International, Inc. reported impairment charges for the first quarter ended March 30, 2024. for the quarter, the company reported long-lived asset impairment charges of $5,432,000 against $10,460,000 a year ago.
Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
217.2 USD | -0.16% | -1.99% | -8.12% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.12% | 11.19B | |
+67.53% | 63.85B | |
-0.77% | 41.83B | |
+45.66% | 40.65B | |
-10.72% | 27.12B | |
+13.30% | 26.52B | |
-22.79% | 18.69B | |
+4.70% | 12.73B | |
+24.10% | 12.11B | |
+27.41% | 12.07B |
- Stock Market
- Equities
- CRL Stock
- News Charles River Laboratories International, Inc.
- Charles River Laboratories International, Inc. Reports Impairment Charges for the First Quarter Ended March 30, 2024